Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,504 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic markers of pigmentation are novel risk loci for uveal melanoma.
Ferguson R, Vogelsang M, Ucisik-Akkaya E, Rai K, Pilarski R, Martinez CN, Rendleman J, Kazlow E, Nagdimov K, Osman I, Klein RJ, Davidorf FH, Cebulla CM, Abdel-Rahman MH, Kirchhoff T. Ferguson R, et al. Sci Rep. 2016 Aug 8;6:31191. doi: 10.1038/srep31191. Sci Rep. 2016. PMID: 27499155 Free PMC article.
Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.
Chat V, Ferguson R, Simpson D, Kazlow E, Lax R, Moran U, Pavlick A, Frederick D, Boland G, Sullivan R, Ribas A, Flaherty K, Osman I, Weber J, Kirchhoff T. Chat V, et al. Among authors: ferguson r. Cancer Immunol Immunother. 2019 Jun;68(6):897-905. doi: 10.1007/s00262-019-02318-8. Epub 2019 Mar 12. Cancer Immunol Immunother. 2019. PMID: 30863922 Free PMC article.
Tumor immunogenomic signatures improve a prognostic model of melanoma survival.
Morales L, Simpson D, Ferguson R, Cadley J, Esteva E, Monson K, Chat V, Martinez C, Weber J, Osman I, Kirchhoff T. Morales L, et al. Among authors: ferguson r. J Transl Med. 2021 Feb 17;19(1):78. doi: 10.1186/s12967-021-02738-0. J Transl Med. 2021. PMID: 33596955 Free PMC article.
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, Weber J. Khushalani NI, et al. Among authors: ferguson r. J Immunother Cancer. 2022 Nov;10(11):e005684. doi: 10.1136/jitc-2022-005684. J Immunother Cancer. 2022. PMID: 36450385 Free PMC article. Clinical Trial.
1,504 results